On September 21, 2026, BNP Paribas SA acquired 19.00 million shares of PHARMARON (03759) (H shares) by way of taking a security interest in shares, linked to convertible bond related derivative transactions. This was an off-exchange transaction and not a direct secondary-market dealing.
Prior to the acquisition, BNP Paribas SA's long position in PHARMARON was 15.67 million shares, representing 4.38%; following the acquisition, the holding changed to 19.00 million shares, with the long position ratio rising to 5.31%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments